Showing 2311-2320 of 6036 results for "".
- Novel Approaches to Cataract Surgery are Challenging Phaco; Cost May Determine Their Successhttps://modernod.com/news/novel-approaches-to-cataract-surgery-are-challenging-phaco-cost-may-determine-their-success/2476591/Ultrasonic phacoemulsification (USP) has been the dominant method of cataract surgery globally over the past half century, but novel alternative approaches are attempting to improve or replace it, according to a Market Scope report. These include robotic cataract machines, ultrasonic-less
- SightGlass Vision Presents Clinical Trial Data From Novel Lenses to Control Myopiahttps://modernod.com/news/sightglass-vision-presents-clinical-trial-data-from-novel-lenses-to-control-myopia/2476541/SightGlass Vision announced that data assessing the tolerability of three iterations of its novel lenses designed to control nearsightedness in children were presented at the Association for Research in Vision and
- IBM’s New AI Technique Could Detect Glaucoma Earlierhttps://modernod.com/news/ibms-new-ai-technique-could-detect-glaucoma-earlier/2476530/At ARVO, IBM researchers presented new techniques in deep learning that could help unlock earlier glaucoma detection. IBM and NYU’s research demonstrates how deep learning models can be trained to learn from and analyze easily-obtained retina images, and then use this analysis to directly estimat
- SynergEyes Launches Tangible Hydra-PEG Coating on SynergEyes VS Scleral Lenshttps://modernod.com/news/synergeyes-launches-tangible-hydra-peg-coating-on-synergeyes-vs-scleral-lens/2476394/SynergEyes announced that the SynergEyes VS scleral lens is now available with Tangible Hydra-PEG on Contamac material. The Tangible Hydra-PEG coating is designed to solve the problem of contact lens discomfort and dry eyes by minimizing deposits and lens fogging, increasing lens surface water re
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i
- Pr3vent Completes Series A Financing Led By InFocus Capital Partnershttps://modernod.com/news/pr3vent-completes-series-a-financing-led-by-infocus-capital-partners/2476301/Pr3vent, a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners. The announcement comes on the heels of a successful seed round in October 2018 led by the joint investment of Skyview Ventures and Tro
- Janssen Enters License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseaseshttps://modernod.com/news/janssen-enters-license-agreement-with-meiragtx-to-develop-gene-therapy-programs-for-inherited-retinal-diseases/2476340/The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings, a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leadin
- Tangible Science Introduces Lens Care System for Custom Contact Lenses Coated with Tangible Hydra-PEGhttps://modernod.com/news/tangible-science-introduces-lens-care-system-for-custom-contact-lenses-coated-with-tangible-hydra-peg/2479600/Tangible Science will be unveiling at the Global Specialty Lens Symposium this week its complete system of products designed to ensure that custom contact lenses coated with Tangible Hydra-PEG offer benefit for the prescribed life of the lenses. Tangible Hydra-PEG is a unique polymer coati